HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the...
Hence then, the article about akeso receives fifth breakthrough therapy designation from nmpa for ivonescimab in first line treatment of advanced biliary tract cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer )
Also on site :
- 'Love Island USA': Carl Defends Trinity After Recoupling Argument With Tierra
- Trump threatens Iran ‘will no longer exist’ for ceasefire violation
- 1972 Rock Classic, Never Recorded in the Studio, Remains a Timeless 4th of July Anthem 54 Years Later